CD4 and neoplasm: In blood, mice that rejected tumors showed decreased naive and central memory T cells [flow cluster (FC1)1-T naive/Tcm] and increased PD1Low effector memory CD4 T cells (FC2-Tem-PD1Low), suggesting more robust T-cell activation compared to mice with tumor progression (Supplementary Fig. 4C, E).